Drugs

FDA Initiatives Help Early-Phase Cancer Trials: Post

FDA Oncology Center of Excellence initiatives such as Project Optimus and Project FrontRunner can help advance patient-centered regulatory decision-making through innovation and collaboration. That’s the view of IQVIA Biotech senior director David Cameron writing in an online Clinical Leader post.

Cameron says the initiatives encourage a more structured approach to determining the right dose and selecting the best patient population to evaluate earlier in the treatment continuum.

He devotes most of his post to Project FrontRunner, which he describes as a “transformative initiative aimed at accelerating the development of oncology therapies by shifting the focus to earlier lines of treatment.”

Project FrontRunner challenges the traditional drug development model, Cameron writes, which historically introduced new oncology therapies in late-stage treatment settings. Instead, he says, “This initiative shifts the focus to earlier lines of therapy, particularly in advanced or metastatic diseases. The goal is to provide patients with earlier access to innovative treatments, generate robust clinical evidence to support benefit/risk assessments, and promote collaborative innovation by encouraging sponsors to work closely with regulators and stakeholders.”

While Project FrontRunner holds immense promise, Cameron concludes, it comes with challenges. “Achieving regulatory alignment across international agencies, funding large-scale trials based on early-phase data, and finding consenting patients for novel therapies in the first-line setting are significant hurdles,” he says. “However, the initiative’s alignment with innovative trial designs and regulatory priorities opens the door to faster, more effective cancer treatments. As more data emerges and successful case studies are published, the adoption of Project FrontRunner is likely to increase, cementing its role in the future of oncology.”

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome